Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
GeoVax Labs (GOVX)
NASDAQ:GOVX
Holding GOVX?
Track your performance easily
Earnings Data
Report Date
Mar 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.77Last Year’s EPS
-$3.94Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: -29.54%
|Next Earnings Date:Mar 26, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including a major BARDA award and progress in clinical trials, contributing to increased revenue and reduced net loss. However, challenges such as increased R&D expenses and delays in trial start dates were also noted.Company Guidance
During the GeoVax Q3 2024 earnings call, several key metrics and strategic advancements were highlighted. The company announced a significant BARDA Project NextGen award valued at almost $400 million, supporting the GEO-CM04S1 COVID-19 vaccine in a comparative trial against an FDA-authorized mRNA vaccine. In Q3, GeoVax reported $2.8 million in revenues, contributing to $3.1 million for the nine-month period, with research and development expenses at $16.1 million, an 11% increase from 2023. General and administrative expenses decreased by 17% to $3.8 million, while the net loss for the first nine months was approximately $16.7 million. The company also advanced its GEO-MVA vaccine against Mpox and smallpox, and continued the development of Gedeptin, with plans for a Phase II trial in head and neck cancer patients. The financial outlook includes using BARDA-supported funding to continue these initiatives, with cash balances rising to $8.6 million as of September 30, 2024.BARDA Project NextGen Award
GeoVax received a BARDA Project NextGen award valued at almost $400 million, supporting their GEO-CM04S1 vaccine in a 10,000-patient trial. This represents a significant milestone and validation of their MVA technology.
Phase II Trial Plans for Gedeptin
Plans were announced to conduct a Phase II trial of Gedeptin in combination with an immune checkpoint inhibitor for head and neck cancer, demonstrating progress in their cancer therapy pipeline.
Increased Revenue
GeoVax reported $2.8 million in revenues for Q3 2024, compared to no comparable revenues in 2023, primarily due to the BARDA contract.
Reduction in Net Loss
Net loss for the first 9 months of 2024 was approximately $16.7 million, a decrease from $18.4 million in 2023, primarily driven by manufacturing activities and BARDA contract costs.
---
GOVX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GOVX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $3.25 | $2.70 | -16.92% |
| Aug 06, 2024 | $1.80 | $1.78 | -1.11% |
| May 14, 2024 | $1.70 | $1.72 | +1.18% |
| Feb 29, 2024 | $2.56 | $2.54 | -0.78% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does GeoVax Labs (GOVX) report earnings?
GeoVax Labs (GOVX) is schdueled to report earning on Mar 26, 2025, TBA Not Confirmed.
What is GeoVax Labs (GOVX) earnings time?
GeoVax Labs (GOVX) earnings time is at Mar 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GOVX EPS forecast?
GOVX EPS forecast for the fiscal quarter 2024 (Q4) is -$0.77.
---